M&A Update – June 9

– NUVL to be acquired by GSK for $124.00 cash per share, 40.1% premium, $9.4 billion
– CPRX / Angelini Pharma filed DEFM14a, vote July 8, closing Q3 2026
– WBD / PSKY / UK CMA phase 1 launched
– XOMA / LGND filed S-4/a, vote July 13, closing Q3 2026
– RUP vote